Breaks Categories: News

ThursdaySep 21, 2017 1:59 pm

NetworkNewsBreaks – GB Sciences, Inc. (GBLX) Forges Innovative Partnership with LSU AgCenter to Advance Understanding of Cannabis

GB Sciences, Inc. (OTCQB: GBLX) and Louisiana State University ("LSU") AgCenter recently announced an agreement with GB Sciences Louisiana, LLC, a wholly owned subsidiary of GB Sciences, Inc., to produce medical cannabis products for qualifying patients. The agreement, conducted under compliance with the Alison Neustrom Act, will allow GB Sciences to produce medical cannabis under the AgCenter’s license. In a news release, GB Sciences, Inc. stated that the agreement is “historic” and creates a formidable partnership. GB Sciences is a publicly traded cannabis company firmly rooted in science. This partnership with LSU, a major research university, is dedicated to advancing…

Continue Reading

ThursdaySep 21, 2017 11:52 am

NetworkNewsBreaks – Tantech Holdings Ltd.’s (NASDAQ: TANH) Subsidiary Secures $20M Electric Vehicle Order

Tantech Holdings (NASDAQ: TANH) this morning said that its 70% owned subsidiary, Suzhou E Motors Buses Co., Ltd., has signed sales contracts for its electric vans and buses worth approximately $20 million. Per the contracts, Zhenjiang Baichuan New Energy Automobile Co., Ltd. intends to purchase 450 all-electric vans and 10 all-electric buses from Tantech with a projected unit sales price of U.S. $43,077. In addition to the unit sales price, Tantech may be eligible to receive Chinese government subsidies for electric car sales. Tantech is expecting to deliver the order by the end of 2017. "In addition to manufacturing a…

Continue Reading

ThursdaySep 21, 2017 11:50 am

NetworkNewsBreaks – Onconova Therapeutics, Inc. (NASDAQ: ONTX) Enters Strategic Collaboration with Cellectar Biosciences, Inc. (NASDAQ: CLRB) to Develop New PDCs

Shares of Onconova Therapeutics (NASDAQ: ONTX) are up 6% after the company this morning said it has entered into a strategic collaboration with Cellectar Biosciences (NASDAQ: CLRB) to develop new phospholipid drug conjugates (PDCs). The companies intend to combine Cellectar’s patented phospholipid ether delivery platform with select proprietary compounds or payloads from Onconova’s early stage product pipeline. Per the terms of the collaboration, Onconova will provide several compounds to Cellectar, which will then link to its PDC platform to create new, more precisely targeted antitumor agents. “We are focused on optimizing the delivery of our therapeutic compounds in the battle…

Continue Reading

ThursdaySep 21, 2017 11:45 am

NetworkNewsBreaks – 92 Resources Corp. (TSX.V: NTY) (OTCQB: RGDCF) Acquires Three New Lithium Properties in Quebec

92 Resources Corp. (TSX.V: NTY) (OTCQB: RGDCF) (FSE: R9G2) today announced the acquisition of three highly prospective hard-rock lithium properties in the James Bay region of Quebec, Canada. The properties, consisting of a combined 115 mineral claims on approximately 14,710 acres, complement the company’s asset portfolio of lithium-bearing spodumene-bearing pegmatite resources. “As we continue to aggressively advance our flagship Hidden Lake Lithium Project in NWT (Northwest Territories), we feel it is critical to maintain a pipeline of additional high-quality, early-staged, lithium pegmatite projects, each with potential as stand-alone opportunities,” Adrian Lamoureux, CEO of 92 Resources, said in a news release.…

Continue Reading

ThursdaySep 21, 2017 9:19 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has been included in the CSE25 Index after qualifying as one of the 25 largest companies in the CSE Composite Index. Per the update, the CSE25 Index is a subgroup of the CSE Composite Index, which was launched in 2015 and currently includes nearly half of the exchange’s listed companies and over 75 percent of the trading activity on the Canadian Securities Exchange. The CSE25 Index includes the top 25 securities contained within the CSE Composite Index based on market capitalization. According to the…

Continue Reading

WednesdaySep 20, 2017 2:37 pm

NetworkNewsBreaks – HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) Strengthens IP Portfolio with Two New Method Patents Covering Technology

Shares of HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) are up 13% after the company this morning said it has been issued two new U.S. patents by the United States Patent and Trademark Office covering the company’s technology and applications of its technology. The first patent, entitled Molecular Malignancy in Melanocytic Lesions (U.S. Patent 9,758,829), was issued to HTG and the John Wayne Cancer Institute, who co-invented the technology. The patent claims a method of treatment on an indeterminate or atypical nevi that involves measuring the nucleic acid expression of certain biomarkers, including MAGEA2, PRAME, PDIA4, NR4A1, PDLIM7, B4GALT1, SAT1, RUNX1,…

Continue Reading

WednesdaySep 20, 2017 11:15 am

NetworkNewsBreaks – Terra Tech Corp. (TRTC) Signs Second Craft Cultivator to Grow Proprietary Cannabis Brand

Terra Tech Corp. (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, recently announced a new farm partnership with a second Craft Cultivator to grow the company’s proprietary high grade “IVXX” cannabis flowers and oils. The farm, Cultivar Inc., located in Salinas, California, is approved for up to six acres (approximately 244,000 square feet) of cannabis cultivation in high tech, climate-controlled greenhouses. “We selected Cultivar to be our newest Cannabis Craftsman as it uses an all-natural cultivation methodology that upholds the high standards associated with our proprietary IVXX brand, including sustainable farming practices and the production of pesticide-free cannabis products,” Derek…

Continue Reading

WednesdaySep 20, 2017 9:14 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Director Featured in SmallCapVoice Interview

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its director of investor relations, Alan Klitenic, was featured in a recent interview with SmallCapVoice.com. In the interview, which can be heard at http://nnw.fm/flQB8, Klitenic discusses CIIX’s recent news, including updates related to the digital currency industry, the company’s plans to launch a Chinese daily video news broadcast from the NYSE floor, CIIX’s recent financial performance and its completion of the record filing process with the Chinese FDA related to its soon-to-be-launched hemp infused skin care line. “I want to emphatically state that CIIX is ready to make sales…

Continue Reading

TuesdaySep 19, 2017 12:07 pm

NetworkNewsBreaks – MassRoots, Inc. (MSRT) Plans to Expand Point of Sale System to Nevada Cannabis Market

MassRoots, Inc. (OTCQB: MSRT), one of the leading technology platforms for the cannabis industry, recently reported that it is expanding its point of sale system to the Nevada cannabis market. The decision by Nevada regulators to require all state-licensed cannabis businesses to file regulatory reports via Franwell, Inc.’s METRC system, replacing MJ Freeway’s Leaf Data Systems, effective November 1, 2017, presented MassRoots with an exciting growth opportunity, the company said in a news release. “We believe MassRoots is uniquely positioned to serve cannabis-related businesses in medical and recreational markets across the United States. We estimate our market-share of cannabis consumers…

Continue Reading

TuesdaySep 19, 2017 12:04 pm

NetworkNewsBreaks – Novavax, Inc. (NASDAQ: NVAX) Enrolls First Participant in Phase 1/2 Trial of NanoFlu™ Vaccine

Novavax (NASDAQ: NVAX) said this morning that it has enrolled the first participant in its phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M™ adjuvant (NanoFlu™) in older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu in comparison to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD). Data from the trial is expected by the end of 2017. “Our goal is to deliver a differentiated flu vaccine to the greater than $3 billion global seasonal influenza commercial market and…

Continue Reading